Guardant Health’s InfinityAI Real-World Evidence Supports Approval of ENHERTU® for Previously Treated Patients with HER2-Positive Metastatic Solid Tumors in Japan
Go back to Guardant Health’s InfinityAI Real-World Evidence Supports Approval of ENHERTU® for Previously Treated Patients with HER2-Positive Metastatic Solid Tumors in Japan| Textainer Group Holdings limited (NASDAQ: GH) | Delayed: 128.83 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $128.83 | 52 Week High | $5.84 | |||
| Open | $128.83 | 52 Week Low | $5.49 | |||
| Day High | $128.83 | P/E | N/A | |||
| Day Low | $128.83 | EPS | $0.00 | |||
| Volume | 270 | |||||
